Mundipharma has announced a licensing agreement with Korean biomedical firm, Genewel , to market and distribute its GUARDIX-SG Surgical Adhesion Barrier portfolio across Southeast Asia.

First developed in Korea in 2010, it is a sterile, transparent, colorless adhesion barrier, formulated as a thermosensitive gel that remains as a solution at room temp but turns to viscous gel on contact with body temperature. 

GUARDIX-SG is indicated as an adjunct in spine, thyroid and abdominal cavity surgeries to reduce the incidence, extent and severity of post-operative adhesions at the surgical site. 

“As a scientifically-proven, safe treatment that provides surgeons with another option and supports patients’ healing process following operations, GUARDIX-SG is a welcome addition to our expanding treatment portfolio,” says Mundipharma CEO, Raman Singh.

“As an organisation, we’re always evaluating innovative treatments that possess significant potential to improve outcomes for patients. GUARDIX-SG meets this criterion, and will be of benefits to surgeons and patients across Southeast Asia, so we’re delighted to have signed this agreement with Genewel.”